CompletedInterventionalNot ApplicableUpdated Jan 13, 2016
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% | NCT00595543 | Trialant
CompletedInterventionalPhase 4Updated Mar 19, 2009
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
ClinicalTrials.gov ID
NCT00595543
Lead Sponsor
Bp Consulting, IncNETWORK
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Enrollment
166Estimated
Last Update Posted
Mar 19, 2009Estimated
Start Date
Jan 2008
Primary Completion Date
Mar 2009Actual
Completion Date
Mar 2009Actual
Brief Summary
To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5% ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.
Acute Pseudophakic Cystoid Macular Edema
Bromfenac
Ketorolac
Diclofenac
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients must be diagnosed with acute pseudophakic CME within 12 months of cataract surgery
Males and females 18 years and older
Able to provide written informed consent
Exclusion Criteria:
Complicated cataract surgery, particularly posterior capsule rupture and vitreous loss
Pre-Existing macular pathology, including macular edema, macular scar, macular hole, or macular pucker
History of Uveitis
Ipsilateral intraocular surgery prior to cataract surgery